Differential influences of gastric bypass and sleeve gastrectomy on plasma nesfatin-1 and obestatin levels in patients with type 2 diabetes mellitus

Current Pharmaceutical Design

Volumn 19, Issue 32, 2013, Pages 5830-5835

  Lee, Wei Jei ^a   Chen, Chih Yen ^b,c   Ser, Kong Han ^a   Chong, Keong ^a   Chen, Shu Chun ^a   Lee, Pui Ching ^c   Liao, You Di ^d   Lee, Shou Dong ^b,c,e  

^a MIN SHENG GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^e CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

Bariatric surgery; Diabetes mellitus; Gastric bypass; Nesfatin 1; Obestatin; Sleeve gastrectomy

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; NESFATIN 1 PROTEIN; OBESTATIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; DIABETIC OBESITY; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; LAPAROSCOPIC SURGERY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SLEEVE GASTRECTOMY; STOMACH BYPASS; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; CALCIUM-BINDING PROTEINS; DIABETES MELLITUS, TYPE 2; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GASTRIC BYPASS; GHRELIN; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84884278042     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113198880010     Document Type: Article

References (40)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
2. Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Lee YC. Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi-institutional international study. J Gastrointest Surg 2012; 16: 45-51.
3. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-85.
4. Chen CY, Lee WJ, Chong K, Lee SD, Liao YD. Impact of intracerebroventricular obestatin on plasma acyl ghrelin, des-acyl ghrelin and nesfatin-1 levels and on gastric emptying in rats. Mol Med Rep 2012; 6: 191-6.
5. Chen CY, Fujimiya M, Laviano A, Chang FY, Lin HC, Lee SD. Modulation of ingestive behavior and gastrointestinal motility by ghrelin in diabetic animals and humans. J Chin Med Assoc 2010; 73: 225-9.
6. Oh I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-12.
7. Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009; 150: 232-8.
8. Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depotspecific adipokine with increased levels in obesity. Endocrinology 2010; 151: 3169-80.
9. Shimizu H, Oh I S, Hashimoto K, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 2009; 150: 662-71.
10. Atsuchi K, Asakawa A, Ushikai M, et al. Centrally administered nesfatin-1 inhibits feeding behaviour and gastroduodenal motility in mice. Neuroreport 2010: 21: 1008-11.
11. Ogiso K, Asakawa A, Amitani H, et al. Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa. Peptides 2011; 32: 150-3.
12. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-9.
13. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 2010; 159: 72-7.
14. Tsuchiya T, Shimizu H, Yamada M, et al. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in nonobese males. Clin Endocrinol (Oxf) 2010; 73: 484-90.
15. Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2011; 7: 683-90.
16. Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146: 143-8.
17. Tan BK, Hallschmid M, Kern W, Lehnert H, Randeva HS. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 2011; 96: E669-73.
18. Gonzalez R, Tiwari A, Unniappan S. Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 2009; 381: 643-8.
19. Gonzalez R, Perry RL, Gao X, et al. Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats. Endocrinology 2011; 152: 3628-37.
20. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391: 1039-42.
21. Chen X, Dong J, Jiang ZY. Nesfatin-1 influences the excitability of glucosensing neurons in the hypothalamic nuclei and inhibits the food intake. Regul Pept 2012; 177: 21-6.
22. Yang M, Zhang Z, Wang C, et al. Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPk/TORC2 pathway in diet-induced insulin resistance. Diabetes 2012; 61: 1959-68.
23. Guo ZF, Zheng X, Qin YW, Hu JQ, Chen SP, Zhang Z. Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab 2007; 92: 1875-80.
24. Nakahara T, Harada T, Yasuhara D, et al. Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biol Psychiatry 2008; 64: 252-5.
25. Ren AJ, Guo ZF, Wang YK, et al. Inhibitory effect of obestatin on glucose-induced insulin secretion in rats. Biochem Biophys Res Commun 2008; 369: 969-72.
26. Green BD, Irwin N, Flatt PR. Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. Peptides 2007; 28: 981-7.
27. St-Pierre DH, Settanni F, Olivetti I, et al. Circulating obestatin levels in normal and Type 2 diabetic subjects. J Endocrinol Invest 2010; 33: 211-4.
28. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012; 120: 91-5.
29. Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S. Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet β-and MIN6 cells. J Endocrinol 2011; 208: R9-16.
30. Uehara M, Yasuhara D, Nakahara T, et al. Increase in energy intake leads to a decrease in obestatin in restricting-type of anorexia nervosa. Exp Clin Endocrinol Diabetes 2011; 119: 536-9.
31. Wang W, Liou TH, Lee WJ, Hsu CT, Lee MF, Chen HH. ESR1 gene and insulin resistance remission are associated with serum uric acid decline for severely obese patients undergoing bariatric surgery. Surg Obes Relat Dis 2012, Nov 14 [Epub ahead of print]
32. Stefater MA, Wilson-Pérez HE, Chambers AP, Sandoval DA, Seeley RJ. All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev 2012; 33: 595-622.
33. Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 2009; 61: 430-81.
34. Sandoval DA, Obici S, Seeley RJ. Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov 2009; 8: 386-98.
35. Könczöl K, Pintér O, Ferenczi S, et al. Nesfatin-1 exerts long-term effect on food intake and body temperature. Int J Obes (Lond) 2012; 36: 1514-21.
36. Yosten GL, Redlinger L, Samson WK. Evidence for a role of endogenous nesfatin-1 in the control of water drinking. J Neuroendocrinol 2012; 24: 1078-84.
37. Chen CY, Tsai CY, Lee WJ, et al. Intracerebroventricular O-noctanoylated ghrelin and its splice variant-induced feeding is blocked by insulin, independent of obestatin or CRF receptor, in satiated rats. Nutrition 2012; 28: 812-20.
38. Ataka K, Inui A, Asakawa A, Kato I, Fujimiya M. Obestatin inhibits motor activity in the antrum and duodenum in the fed state of conscious rats. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1210-8.
39. Chen CY, Huang SC. Lack of direct effects of acyl ghrelin, desacyl ghrelin, and obestatin on rat lower esophageal sphincter motility in vitro. J Chin Med Assoc 2011; 74: 394-9.
40. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 2013, Feb 25 [Epub ahead of print]